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HLA‑A alleles including HLA‑A29 
affect the composition of the gut 
microbiome: a potential clue 
to the pathogenesis of birdshot 
retinochoroidopathy
Peter R. Sternes1, Tammy M. Martin2, Michael Paley3, Sarah Diamond4, Mark J. Asquith4,7, 
Matthew A. Brown5 & James T. Rosenbaum4,6*
Birdshot retinochoroidopathy occurs exclusively in individuals who are HLA-A29 positive. The 
mechanism to account for this association is unknown. The gut microbiome has been causally 
implicated in many immune‑mediated diseases. We hypothesized that HLA-A29 would affect the 
composition of the gut microbiome, leading to a dysbiosis and immune‑mediated eye disease. Fecal 
and intestinal biopsy samples were obtained from 107 healthy individuals from Portland, Oregon 
environs, 10 of whom were HLA-A29 positive, undergoing routine colonoscopy. Bacterial profiling 
was achieved via 16S rRNA metabarcoding. Publicly available whole meta‑genome sequencing data 
from the Human Microbiome Project (HMP), consisting of 298 healthy controls mostly of US origin, 
were also interrogated. PERMANOVA and sparse partial least squares discriminant analysis (sPLSDA) 
demonstrated that subjects who were HLA-A29 positive differed in bacterial species composition 
(beta diversity) compared to HLA-A29 negative subjects in both the Portland (p = 0.019) and HMP 
cohorts (p = 0.0002). The Portland and HMP cohorts evidenced different subsets of bacterial species 
associated with HLA-A29 status, likely due to differences in the metagenomic techniques employed. 
The functional composition of the HMP cohort did not differ overall (p = 0.14) between HLA-A29 
positive and negative subjects, although some distinct pathways such as heparan sulfate biosynthesis 
showed differences. As we and others have shown for various HLA alleles, the HLA allotype impacts 
the composition of the microbiome. We hypothesize that HLA-A29 may predispose chorioretinitis via 
an altered gut microbiome.
HLA molecules affect the susceptibility to at least 100  diseases1,2. Although HLA molecules play an essential role 
in antigen presentation, in most instances, the mechanisms by which HLA molecules predispose to disease are 
unknown. One hypothesis is that HLA molecules could affect disease susceptibility indirectly by shaping the 
composition of the gut  microbiome3,4. The microbiome plays a major role in exposing the immune system to a 
wide range of antigens and thus educating  it4,5. A teleological argument is that the tremendous polymorphism of 
the major histocompatibility system minimizes the risk that an infectious pathogen could eliminate all members 
of a species. We and others have shown that indeed one’s HLA type has an impact on which bacteria are present 
in the  gut3,6–10. For example, HLA-B27 which predisposes to ankylosing spondylitis and HLA-DRB1 alleles associ-
ated with rheumatoid arthritis each have effects on the intestinal  microbiome3.
Birdshot retinochoroidopathy (BSRC) is a vision-threatening, immune-mediated inflammation of the poste-
rior uveal  tract11. It occurs exclusively in individuals who have the HLA allele,  A2912–15. HLA-A29 might increase 
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the risk to develop BSRC more than 200-fold16. We hypothesized that the effect of HLA-A29 on disease suscep-
tibility might be an indirect mechanism through an alteration of the gut microbiome. We tested this hypothesis 
by characterizing the microbiome in HLA-A29 healthy individuals compared to HLA-A29 negative controls.
Methods
Human participants. This study utilized collected human samples collected in previous studies. As 
described by Asquith et al.  20193, the Portland cohort consisted of 107 subjects, aged 40–75, predominately Cau-
casian (~ 90%), typically following an omnivorous diet (~ 95%) and were undergoing routine colorectal cancer 
screening at Oregon Health & Science University’s Center for Health and Healing were included in this study. 
Individuals were excluded if they had a personal history of inflammatory bowel disease or colon cancer, prior 
bowel or intestinal surgery or were pregnant. Ethical approval for this study was obtained from the Oregon 
Health & Science University Institutional Review Board (IRB). Written informed consent was obtained from all 
subjects. This study was performed in accordance with all applicable US federal and state regulations, following 
the tenants of the Declaration of Helsinki, are as previously  described3.
For the Human Microbiome Project (HMP) cohort, sample collection, storage, handling, and whole-metage-
nome sequencing were performed as in the  HMP117. Minimally perturbed microbiomes from 149 men and 151 
women, mean age 26 years, mean BMI 24 kg/m2 and predominately Caucasian with strict inclusion and exclu-
sion criteria (such as presence of systemic diseases, use of immunomodulators and recent use of antibiotics or 
probiotics) were sampled from multiple body sites at either two or three timepoints. Approval for this study was 
granted by the Institutional Review Boards of the two recruitment centers (Baylor College of Medicine, Houston, 
TX and Washington University, St. Louis, MO) and informed written consent was attained. Further details on 
IRB review, informed consent, subject exclusion criteria, the sampling protocols, and timeline can be found in 
previous  publications2,17,18.
Sample and data processing. For the Portland cohort, 568 stool and biopsy samples across 107 individu-
als were extracted and amplified for the bacterial marker gene 16S rRNA, as previously  described3. Paired end 
reads were joined, quality filtered and analysed using Quantitative Insights Into Microbial Ecology (QIIME) 
v1.9.119. Operational taxonomy units (OTU) were picked against a closed reference and taxonomy was assigned 
using the Greengenes database (gg_13_8)20, clustered at 97% similarity by  UCLUST21 and low abundance OTUs 
were removed (< 0.01%). Genotyping was performed on DNA extracted from mucosal biopsies and genotyped 
using Illumina CoreExome SNP microarrays according to standard protocols. Bead intensity data were pro-
cessed and normalized for each sample, and genotypes called using Genome Studio (Illumina). We imputed 
HLA-A genotypes using  SNP2HLA22, as previously  reported23.
For the HMP cohort, metadata were collected with permission from the Database of Genotypes and Pheno-
types (dbGaP; https ://www.ncbi.nlm.nih.gov/gap) with the accession number phs000228.v4.p1. Precomputed 
metagenomic profiles and basic subject metadata were collected through the HMP Data Analysis and Coordina-
tion Center (HMP DACC; https ://hmpda cc.org), as described by Lloyd-Price et al.  201724.
Data visualization and statistical analysis. Multidimensional data visualisation of beta diversity was 
conducted using a sparse partial least squares discriminant analysis (sPLSDA) on arcsine squared root trans-
formed data, as implemented in R v3.5.225 as part of the MixOmics package v6.3.126. Association of the micro-
bial composition (beta diversity) with metadata of interest was conducted using a PERMANOVA test as part of 
vegan v2.4–527 on arcsine square root transformed data at species level, taking into account individual identity 
where multiple sites per individual were co-analysed, as well as the sources of covariation such as BMI, ethnicity, 
age and gender. Alpha diversity was calculated at species level using the rarefy function as implemented in vegan 
v2.4–5 and differences were evaluated using a Wilcoxon rank-sum test. Differential abundance of bacterial taxa 
and MetaCyc pathways were tested for significance using MaAsLin2 v0.2.328. Graphs and figures were generated 
using ggplot2 v3.3.229.
Results
Recently, we demonstrated that carriage of the main risk alleles for ankylosing spondylitis and rheumatoid 
arthritis (HLA-B27 and HLA-DRB1 risk alleles, respectively) correlated with microbiome perturbance in healthy 
 individuals3. It follows that carriage of HLA-A29, the main risk allele for BSRC, may also be correlated with such 
an effect. To investigatee this, we analyzed two independent cohorts of healthy individuals, (1) a cohort of 107 
healthy individuals with samples from six body sites (a.k.a. the Portland Cohort) analyzed via 16S rRNA meta-
barcoding, and (2) a cohort of 298 healthy individuals who have had their stools whole-metagenome sequenced 
as part of the Human Microbiome Project. Detailed descriptions of the cohorts can be found in their previous 
 reports2,17,18 and a broad overview of the cohort according to HLA-A29 status is shown in Table 1.
Similar to our observations for HLA-B27 and HLA-DRB1, we noted a significant differentiation of the overall 
bacterial species (a.k.a. taxonomic) composition in both the Portland (p = 0.019) and HMP (p = 0.0002) cohorts 
whilst accounting for sources of covariation such as age, gender, ethnicity and BMI. Furthermore, consistent 
with previous reports, no differences in the diversity of bacterial species was noted across both cohorts, indicat-
ing that the underlying host genetics may affect the overall composition of the microbiome, but not the overall 
species diversity (Fig. 1A–C). Of particular note was an observed enrichment of Clostridium difficile (q = 0.0007) 
for HLA-A29 positive subjects in the HMP cohort (Supplementary Table 1). Clostridium difficile is well known 
for its ability to cause colitis and potentially associated immune responses to cause disease such as reactive 
 arthritis30. The casual implications of Clostridium difficile enrichment and birdshot retinochoroidopathy may 
therefore warrant further investigation. Testing of other commonly found HLA alleles in the HMP dataset (> 5% 
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allele frequency; -A1, -A2, -A3, -A11, -A24, -A26 and -A68) also revealed significant differentiation of the overall 
taxonomic composition (beta diversity, p < 0.01), however the individual bacterial species associated with these 
various HLA-A subtypes were different, in particular no association with Clostridium difficile was found (Sup-
plementary Table 3). These data support allele-specific effects for HLA-A upon the microbiome.
Interrogation of the metabolic/functional composition, enabled by whole-metagenome sequencing informa-
tion from the HMP cohort, did not reveal significant differentiation of the overall composition (beta diversity) 
nor diversity (alpha diversity) (Fig. 1D). Despite no differences in the overall composition, some specific meta-
bolic pathways were significantly different (Supplementary Table 2), notably a potential enrichment of Heparan 
sulfate biosynthesis pathways (q = 0.07).
Discussion
Although HLA molecules are responsible for antigen presentation, the mechanism by which HLA molecules 
predispose to disease is most often unknown. HLA molecules influence susceptibility in some immune-mediated 
diseases such as ankylosing  spondylitis3,  BSRC12, and Crohn’s  disease31 in which auto-antibodies are not a char-
acteristic finding in the disease. This would suggest that in such diseases, the predisposition engendered by the 
HLA allele might not be acting via an autoimmune response. Since the gut microbiome educates the immune 
response and includes a vast array of antigenic diversity, an alternative hypothesis is that HLA molecules in some 
instances predispose to disease via effects on the gut  microbiome4. An alteration in the gut microbiome could 
affect disease susceptibility through a variety of mechanisms such as a change in the balance of T cell subsets, 
migration of lymphocytes from the gut to an affected organ, dysbiosis leading to bacterial antigens leaking from 
the  gut32, or molecular  mimicry4. The vast majority of individuals who are HLA-A29 positive, do not develop 
birdshot  retinochoroidopathy33. Likewise, the majority of individuals who are HLA-B27 positive do not develop 
spondyloarthritis and the majority of individuals who are HLA-DRB1 positive do not develop rheumatoid arthri-
tis. Whilst HLA alleles are major susceptibility factors for many immune-mediated inflammatory diseases, 
many other genetic loci have been associated with disease, notably ERAP1 and ERAP2 in the case of  BSRC34,35. 
Carriage of these risk alleles is necessary, but not sufficient, for disease which suggests that the presence of other 
environmental or genetic factors is also required. A notable example of this is celiac disease, for which 30–35% 
of the population carry the HLA-DQ2 and -DQ8 risk alleles, yet only ~ 2–5% of the carriers develop disease. 
Additional non-major histocompatibility complex risk loci have been identified, however their overall genetic 
contribution has been estimated as only 3–4%. Environmental factors such as enteropathic virus and changes in 
bacterial flora have subsequently been shown to favor the development of celiac  disease36.
In this report, we interrogated two separate databases, one derived from the Human Microbiome  Project37, 
and one obtained in Portland, Oregon, USA from healthy subjects undergoing  colonoscopy3. In both instances, 
we found that HLA-A29 affected the bacterial composition of the intestine. We did not compare the effect of 
HLA-A*2901 versus A*2902 since no HLA-A*2901 individuals were found in the analyzed cohorts. Whilst both 
databases showed microbiome differences in HLA-A29 carriers, differences in findings for specific bacterial 
species occurred between the databases. However, in this circumstance, direct inter-cohort comparison is not 
entirely valid given the differences in cohort demographics (such as age and BMI) as well as statistical power 
and methodological differences, as the HMP data are based on whole-metagenome sequencing while the Port-
land data are based on 16S metabarcoding. There is precedent to indicate that these different methodologies 
produce alternative  results38–40. However, even though the abundance of specific bacterial species cannot be 
directly compared between cohorts, re-confirmation of the broader net effect on taxonomic composition in an 
independent cohort remains possible.
In this study we elected to test the effect of HLA-A29 on the intestinal microbiome in healthy individuals. A 
future study should compare the intestinal microbiome in patients with BSRC with healthy, HLA-A29 positive 
individuals or individuals with other forms of posterior uveitis. The rationale to study healthy subjects is that it 
allows us to analyze specifically the single, most important known risk factor for this form of uveitis. Our data 
offer a plausible mechanism by which HLA-A29 might contribute to the disease. If the intestinal microbiome 
in patients with BSRC does not differ from the microbiome of healthy, HLA-A29 subjects, the other genetic 
factors or environmental factors must contribute via a mechanism that does not involve the microbiome. If 
BSRC patients, on the other hand, have an intestinal microbiome that differs from healthy, HLA-A29 controls, 
a reasonable hypothesis is that additional causal factors also contribute to the predisposition to BSRC via an 
effect on the microbiome.
Table 1.  Characteristics of the analyzed cohorts. Except for gender in the HMP cohort, age, BMI, gender and 
ethnicity were not significantly different between HLA-A29 positive and negative groupings, as measured via 
T-test. All HLA-A29 positive subjects carried the HLA-A29*02 subtype.
HMP cohort Portland cohort
HLA-A29 Pos HLA-A29 Neg p-value HLA-A29 Pos HLA-A29 Neg p-value
Age (Mean ± SD) 25 ± 4.6 26 ± 5.2 0.37 55 ± 6.7 58 ± 7.4 0.3
BMI (Mean ± SD) 24.1 ± 3.6 24.34 ± 3.4 0.8 30.34 ± 8.8 28.23 ± 7.1 0.41
Gender (% Male) 25 53 0.02 40 46 0.7
Ethnicity (% White) 95 81 0.13 90 90 0.98
Count 21 277 – 10 97 –
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Figure 1.  (A) sPLSDA and PERMANOVA analysis of bacterial species composition (beta diversity) of the 
Portland cohort. Controlling for covariates (gender, ethnicity, age and BMI) and accounting for repeated 
sampling, significant differentiation of the species composition according to HLA-A29 status was noted. (B) 
Bacterial species richness (alpha diversity) across six sampling sites in the Portland cohort. Consistent with 
results noted for HLA-B27 and HLA-DRB1, carriage of HLA-A29 is not associated with a difference in the 
number of detectable bacterial species. (C) Alpha and beta diversity (sPLSDA and PERMANOVA) analysis of 
bacterial species (a.k.a. taxonomic) composition of the HMP cohort. Controlling for covariates (smoking, age, 
BMI, gender and ethnicity) and accounting for repeated sampling, significant differentiation was noted. No 
difference in alpha diversity was noted. (D) Alpha and beta diversity (sPLSDA and PERMANOVA) analysis of 
the overall metabolic/functional composition of the microbiome for individuals in HMP cohort. No significant 
differences were noted, consistent with observations that the functional composition of the microbiome is 
relatively stable across individuals compared to the taxonomic/species composition. Plots were generated using 
the  mixOmics26 and ggplot2 packages as part of R.
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We recognize that demonstrating that HLA-A29 shapes the microbiome does not prove that the changes in 
the microbiome are causally related to the uveitis. The pathogenesis of BSRC, however, remains unknown. The 
potential contribution of the gut microbiome suggests novel approaches in human and animal models to elucidate 
the cause of this vision-threatening disease.
Received: 30 June 2020; Accepted: 27 August 2020
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